Mixed results for exposure and response prevention therapy in mixed reality for patients with contamination-related obsessive-compulsive disorder: A randomized controlled pilot study
Standard
Mixed results for exposure and response prevention therapy in mixed reality for patients with contamination-related obsessive-compulsive disorder: A randomized controlled pilot study. / Miegel, Franziska; Jelinek, Lena; Moritz, Steffen; Lohse, Luzie; Yassari, Amir H; Bücker, Lara.
In: J CLIN PSYCHOL, Vol. 79, No. 10, 10.2023, p. 2317-2336.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mixed results for exposure and response prevention therapy in mixed reality for patients with contamination-related obsessive-compulsive disorder: A randomized controlled pilot study
AU - Miegel, Franziska
AU - Jelinek, Lena
AU - Moritz, Steffen
AU - Lohse, Luzie
AU - Yassari, Amir H
AU - Bücker, Lara
N1 - © 2023 Wiley Periodicals LLC.
PY - 2023/10
Y1 - 2023/10
N2 - INTRODUCTION: Technology-supported exposure and response prevention (ERP) for patients with obsessive-compulsive disorder (OCD) as tested in clinical research, holds promise but also has limitations. The present study aims to overcome these limitations by using mixed reality for ERP (MERP). The objectives of this pilot study were to evaluate the safety, feasibility, and acceptance of MERP and to identify possible obstacles.METHODS: Twenty inpatients with contamination-related OCD were recruited and randomized to two conditions: MERP (six sessions in 3 weeks) and care as usual treatment. Patients were assessed before treatment (baseline), after the 3-week intervention period (post), as well as 3 months after post assessment (follow-up) regarding symptomatology (Y-BOCS).RESULTS: Results showed a similar reduction in symptomatology in both groups from baseline to post. Regarding safety, no clinically significant deterioration was detected in the MERP group. Patients' evaluation of the MERP was heterogeneous. The qualitative feedback provided helpful indications for further development of the software. Sense of presence was below the midpoint of the scales.CONCLUSION: This is the first study evaluating a MERP for patients with OCD that shows cautious evidence for the acceptance and safety of MERP. The results of the subjective evaluation suggest revisions of the software.
AB - INTRODUCTION: Technology-supported exposure and response prevention (ERP) for patients with obsessive-compulsive disorder (OCD) as tested in clinical research, holds promise but also has limitations. The present study aims to overcome these limitations by using mixed reality for ERP (MERP). The objectives of this pilot study were to evaluate the safety, feasibility, and acceptance of MERP and to identify possible obstacles.METHODS: Twenty inpatients with contamination-related OCD were recruited and randomized to two conditions: MERP (six sessions in 3 weeks) and care as usual treatment. Patients were assessed before treatment (baseline), after the 3-week intervention period (post), as well as 3 months after post assessment (follow-up) regarding symptomatology (Y-BOCS).RESULTS: Results showed a similar reduction in symptomatology in both groups from baseline to post. Regarding safety, no clinically significant deterioration was detected in the MERP group. Patients' evaluation of the MERP was heterogeneous. The qualitative feedback provided helpful indications for further development of the software. Sense of presence was below the midpoint of the scales.CONCLUSION: This is the first study evaluating a MERP for patients with OCD that shows cautious evidence for the acceptance and safety of MERP. The results of the subjective evaluation suggest revisions of the software.
KW - Humans
KW - Pilot Projects
KW - Treatment Outcome
KW - Cognitive Behavioral Therapy/methods
KW - Augmented Reality
KW - Obsessive-Compulsive Disorder/therapy
U2 - 10.1002/jclp.23550
DO - 10.1002/jclp.23550
M3 - SCORING: Journal article
C2 - 37317567
VL - 79
SP - 2317
EP - 2336
JO - J CLIN PSYCHOL
JF - J CLIN PSYCHOL
SN - 0021-9762
IS - 10
ER -